Ataca, P. Et Al. 2014. Favorable Treatment Alternative for Primary Central Nervous System Lymphoma: Combined Chemotherapy Regimen Consisting of High-Dose Methotrexate, Rituximab and Cytosine-Arabinoside. 56th Annual Meeting of the American-Society-of-Hematology , (San-Francisco, Costa Rica).

Ataca, P., TOPRAK, S. K., Atilla, E., TOPÇUOĞLU, P., YÜKSEL, M., KAYGUSUZ, G., ... KUZU, I.(2014). Favorable Treatment Alternative for Primary Central Nervous System Lymphoma: Combined Chemotherapy Regimen Consisting of High-Dose Methotrexate, Rituximab and Cytosine-Arabinoside . 56th Annual Meeting of the American-Society-of-Hematology, San-Francisco, Costa Rica

Ataca, Pinar Et Al. "Favorable Treatment Alternative for Primary Central Nervous System Lymphoma: Combined Chemotherapy Regimen Consisting of High-Dose Methotrexate, Rituximab and Cytosine-Arabinoside," 56th Annual Meeting of the American-Society-of-Hematology, San-Francisco, Costa Rica, 2014

Ataca, Pinar Et Al. "Favorable Treatment Alternative for Primary Central Nervous System Lymphoma: Combined Chemotherapy Regimen Consisting of High-Dose Methotrexate, Rituximab and Cytosine-Arabinoside." 56th Annual Meeting of the American-Society-of-Hematology , San-Francisco, Costa Rica, 2014

Ataca, P. Et Al. (2014) . "Favorable Treatment Alternative for Primary Central Nervous System Lymphoma: Combined Chemotherapy Regimen Consisting of High-Dose Methotrexate, Rituximab and Cytosine-Arabinoside." 56th Annual Meeting of the American-Society-of-Hematology , San-Francisco, Costa Rica.

@conferencepaper{conferencepaper, author={Pinar Ataca Et Al. }, title={Favorable Treatment Alternative for Primary Central Nervous System Lymphoma: Combined Chemotherapy Regimen Consisting of High-Dose Methotrexate, Rituximab and Cytosine-Arabinoside}, congress name={56th Annual Meeting of the American-Society-of-Hematology}, city={San-Francisco}, country={Costa Rica}, year={2014}}